Eczacıbaşı Pharmaceutical and Industrial Investment Co.

Eczacıbaşı is a leading Turkish conglomerate with a dominant presence in the healthcare, building products, and consumer goods sectors. Its healthcare division is a major player in the MENA region, consisting of Gensenta, a large-scale manufacturer of finished pharmaceuticals and APIs, and Eczacıbaşı Pharmaceuticals Marketing, which manages a vast portfolio of licensed and proprietary products. The company is currently executing a 'Healthcare 2.0' strategy, shifting focus from traditional generics toward high-tech sterile injectables, biosimilars, and digital health platforms. This was marked by the 2022 acquisition of Gensenta from Amgen and the 2025 divestment of its nuclear medicine business to focus on biopharmaceutical manufacturing and international export expansion.